(c) 2024 PillSync.com

Hydrochlorothiazide 12.5 MG Lisinopril 10 MG Oral Tablet

INDICATIONS AND USAGE Lisinopril and Hydrochlorothiazide Tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using Lisinopril and Hydrochlorothiazide Tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering use of Lisinopril and Hydrochlorothiazide Tablets, it should be noted that Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non- Blacks (see WARNINGS, Head and Neck Angioedema ).

Actavis Pharma, Inc.


5 years ago ROUND PINK WATSON 860 Hydrochlorothiazide 12.5 MG  Lisinopril 10 MG Oral Tablet

ROUND PINK WATSON 860

5 years ago ROUND PINK WATSON 860 Hydrochlorothiazide 12.5 MG  Lisinopril 10 MG Oral Tablet

WATSON 860 ROUND PINK

HOW SUPPLIED

LISINOPRIL AND HYDROCHLOROTHIAZIDE tablets USP are available as follows: 10 mg/12.5 mg: pink, round, unscored, flat-faced, beveled-edge tablets, debossed “ WATSON ” and “ 860 ” on the periphery of one side and plain on the other side are supplied in bottles of 100 (NDC 0591-0860-01) and 500 (NDC 0591-0860-05). 20 mg/12.5 mg: Light blue, round, unscored, flat-faced, beveled-edge tablets, debossed “ WATSON ” and “ 861 ” on the periphery of one side and plain on the other side are supplied in bottles of 100 (NDC 0591-0861-01) and 500 (NDC 0591-0861-05). 20 mg/25 mg: pink, round, unscored, flat-faced, beveled-edge tablets, debossed “WATSON” and “862” on the periphery of one side and plain on the other side are supplied in bottles of 100 (NDC 0591-0862-01) and 500 (NDC 0591-0862-05). S torage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from excessive light and humidity . Dispense in a tight, light-resistant container according to USP/NF. Brands listed are trademarks of their respective owners. Manufactured in India by: Watson Pharma Private Limited Verna, Salcette Goa 403 722 INDIA Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA Rev. B 5/2020


More pills like ROUND WATSON 860












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site